Post by account_disabled on Mar 6, 2024 2:43:32 GMT -6
Vaccines for the Health of People or Capital? Recent Announcements of Successful Results in Two Covid- Vaccine Clinical Trials Raise Hopes That a Return to But the Current Innovation System Puts the Interests of High-income Countries Before Those of the Rest, and Profits Before Public Health. The First Step Towards a Vaccine Serving the People is to Ensure For Example, High-income Countries Have Already Purchased About % of the Doses of the Pfizer/biontech and Moderna Vaccines That Are Available in the First Year.
In Short, Rich Countries Have Appropriated . Manufacturers, Against . Billion (Including Some Million Doses for Covax) for the Rest of the World. That is, They Reserved Enough Doses to Cover Their Populations Several Times Over, With the UK Mobile Database Possibility That the Remaining Doses Will Not Be Enough to Vaccinate Even the Most Vulnerable Groups in Other Countries. At the Same Time, as the Race for Vaccines is Focused Above All on Western Markets, Some Candidates Would Be Very Unviable Outside of a Developed Country. The Pfizer/biontech One Must Be Kept at - °c, a Temperature Lower Than That of the Antarctic Winter.
The Distribution of This Vaccine Will Create Costly and Complex Logistical Challenges, Especially for Low- and Middle-income Countries. Although Other Candidates (for Example, Astrazeneca-oxford) Are Stable at Higher Temperatures, It is Notable That the First Product to Reach the Approval Phase Includes Such an Obvious Element of Market Discrimination. Beyond National Interests Lurks the Problem of Even Narrower Private Interests, the Product of a Hyper-financialized Pharmaceutical Innovation Model. Now That the Pandemic Gives Investors the Chance for a Windfall, the Industry is Expanding the Business Model to Develop Future Vaccines.
In Short, Rich Countries Have Appropriated . Manufacturers, Against . Billion (Including Some Million Doses for Covax) for the Rest of the World. That is, They Reserved Enough Doses to Cover Their Populations Several Times Over, With the UK Mobile Database Possibility That the Remaining Doses Will Not Be Enough to Vaccinate Even the Most Vulnerable Groups in Other Countries. At the Same Time, as the Race for Vaccines is Focused Above All on Western Markets, Some Candidates Would Be Very Unviable Outside of a Developed Country. The Pfizer/biontech One Must Be Kept at - °c, a Temperature Lower Than That of the Antarctic Winter.
The Distribution of This Vaccine Will Create Costly and Complex Logistical Challenges, Especially for Low- and Middle-income Countries. Although Other Candidates (for Example, Astrazeneca-oxford) Are Stable at Higher Temperatures, It is Notable That the First Product to Reach the Approval Phase Includes Such an Obvious Element of Market Discrimination. Beyond National Interests Lurks the Problem of Even Narrower Private Interests, the Product of a Hyper-financialized Pharmaceutical Innovation Model. Now That the Pandemic Gives Investors the Chance for a Windfall, the Industry is Expanding the Business Model to Develop Future Vaccines.
